Get started
Ventyx Biosciences, Inc.Ventyx Biosciences, Inc.Ventyx Biosciences, Inc.

Ventyx Biosciences, Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

VTYX chart


Full chart

VTYX upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪125.86 M‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−2.37 USD
Net income (FY)
‪−192.96 M‬ USD
Revenue (FY)
0.00 USD
Shares float
‪53.83 M‬
Beta (1Y)
2.26

Employees


Employees (FY)
80
Change (1Y)
+21 +35.59%
Revenue / Employee (1Y)
0.00 USD
Net income / Employee (1Y)
‪−2.41 M‬ USD

About Ventyx Biosciences, Inc.


Sector
Health Technology
Industry
Biotechnology
CEO
Raju S. Mohan
Website
ventyxbio.com
Headquarters
San Diego
Founded
2018
FIGI
BBG00VC84K29
Ventyx Biosciences, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing novel small molecule therapeutics for the treatment of autoimmune diseases. Its clinical stage pipeline includes VTX958, a Phase 1 allosteric TYK2 inhibitor for the treatment of a broad range of autoimmune diseases, VTX002, a Phase 2-ready S1P1 receptor modulator for the treatment of ulcerative colitis, and VTX2735, a Phase 1-ready peripheral inhibitor of the NLRP3 inflammasome, which is a mediator of multiple inflammatory conditions. The company was founded on November 21, 2018 and is headquartered in San Diego, CA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—
‪0.00‬

VTYX news



Ideas



See all ideas 

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of VTYX is 1.72 USD — it has decreased by −3.37% in the past 24 hours. Watch Ventyx Biosciences, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Ventyx Biosciences, Inc. stocks are traded under the ticker VTYX.
VTYX stock has fallen by −18.48% compared to the previous week, the month change is a −32.02% fall, over the last year Ventyx Biosciences, Inc. has showed a −26.81% decrease.
We've gathered analysts' opinions on Ventyx Biosciences, Inc. future price: according to them, VTYX price has a max estimate of 15.00 USD and a min estimate of 1.00 USD. Watch VTYX chart and read a more detailed Ventyx Biosciences, Inc. stock forecast: see what analysts think of Ventyx Biosciences, Inc. and suggest that you do with its stocks.
VTYX reached its all-time high on Mar 3, 2023 with the price of 47.25 USD, and its all-time low was 1.79 USD and was reached on Aug 22, 2024. View more price dynamics on VTYX chart.
See other stocks reaching their highest and lowest prices.
VTYX stock is 5.81% volatile and has beta coefficient of 2.26. Track Ventyx Biosciences, Inc. stock price on the chart and check out the list of the most volatile stocks — is Ventyx Biosciences, Inc. there?
Today Ventyx Biosciences, Inc. has the market capitalization of ‪121.62 M‬, it has decreased by −11.88% over the last week.
Yes, you can track Ventyx Biosciences, Inc. financials in yearly and quarterly reports right on TradingView.
Ventyx Biosciences, Inc. is going to release the next earnings report on Mar 20, 2025. Keep track of upcoming events with our Earnings Calendar.
VTYX earnings for the last quarter are −0.50 USD per share, whereas the estimation was −0.52 USD resulting in a 3.38% surprise. The estimated earnings for the next quarter are −0.54 USD per share. See more details about Ventyx Biosciences, Inc. earnings.
Ventyx Biosciences, Inc. revenue for the last quarter amounts to 0.00 USD, matching the estimated figure, and no changes in revenue are expected for the next quarter.
VTYX net income for the last quarter is ‪−35.25 M‬ USD, while the quarter before that showed ‪−31.95 M‬ USD of net income which accounts for −10.33% change. Track more Ventyx Biosciences, Inc. financial stats to get the full picture.
No, VTYX doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 21, 2024, the company has 80.00 employees. See our rating of the largest employees — is Ventyx Biosciences, Inc. on this list?
Like other stocks, VTYX shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Ventyx Biosciences, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Ventyx Biosciences, Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Ventyx Biosciences, Inc. stock shows the strong sell signal. See more of Ventyx Biosciences, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.